
# Title 42 - Public Health
## Chapter IV - Centers for Medicare & Medicaid Services, Department of Health and Human Services
### Subchapter B - Medicare Program
#### PART 413 - PRINCIPLES OF REASONABLE COST REIMBURSEMENT; PAYMENT FOR END-STAGE RENAL DISEASE SERVICES; PROSPECTIVELY DETERMINED PAYMENT RATES FOR SKILLED NURSING FACILITIES; PAYMENT FOR ACUTE KIDNEY INJURY DIALYSIS
##### Subpart H - Payment for End-Stage Renal Disease (ESRD) Services
###### ยง 413.234 Drug designation process.
####### Type 3 NDA,Type 5 NDA,

(i) Ais for a new dosage form of an active ingredient that has been approved or marketed in the United States (U.S.) by the same or another applicant but in a different dosage form. The indication for the drug product does not need to be the same as that of the already marketed drug product. Once a new dosage form has been approved for an active ingredient, subsequent applications for the same dosage form and active ingredient should be classified as aas described in paragraph (e)(2) of this section.

(ii) [Reserved]

(2) Type 5 NDA-New Formulation or Other Differences.
